These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6400705)

  • 1. Meeting the problems of first-generation insulin infusion pumps: clinical trial of a new miniature infuser.
    Bending JJ; Pickup JC; Keen H; Rothwell D; Sutherland IA
    Diabetes Care; 1983; 6(5):452-8. PubMed ID: 6400705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No pharmacokinetic effect of retaining the infusion site up to four days during continuous subcutaneous insulin infusion therapy.
    Olsson PO; Arnqvist H; Asplund J
    Diabet Med; 1993 Jun; 10(5):477-80. PubMed ID: 8334830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy.
    Chiasson JL; Ducros F; Poliquin-Hamet M; Lopez D; Lecavalier L; Hamet P
    Diabetes Care; 1984; 7(4):331-7. PubMed ID: 6381006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal insulin substitution with glargine or continuous subcutaneous insulin infusion in adult type 1 diabetes patients-a randomized controlled trial.
    Bragd J; von Döbeln A; Lins PE; Adamson U; Bergström J; Oskarsson P
    Diabetes Technol Ther; 2010 Sep; 12(9):689-93. PubMed ID: 20687863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study).
    Derosa G; Catena G; Scelsi L; D'Angelo A; Raddino R; Cosentino E; Maggi A; Pasini G; Borghi C; Maffioli P
    Diabetes Metab Res Rev; 2020 Jan; 36(1):e3219. PubMed ID: 31642581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Short acting insulin analogues for treating diabetic patients with CSII (continuous subcutaneous insulin infusion)].
    Jermendy G
    Orv Hetil; 2006 Nov; 147(46):2223-6. PubMed ID: 17396394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of multiple daily insulin therapy with continuous subcutaneous insulin infusion therapy in adolescents with type 1 diabetes mellitus: a single-center experience from Turkey.
    Abaci A; Atas A; Unuvar T; Demir K; Bober E; Büyükgebiz A
    J Pediatr Endocrinol Metab; 2009 Jun; 22(6):539-45. PubMed ID: 19694201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous Subcutaneous Insulin Infusion in Adult Type 1 Diabetes Mellitus Patients: Results from a Public Health System.
    Moreno-Fernandez J; Gomez FJ; Pinés P; González J; López J; López LM; Blanco B; Roa C; Herranz S; Muñoz-Rodríguez JR
    Diabetes Technol Ther; 2019 Aug; 21(8):440-447. PubMed ID: 31199682
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial.
    Hoogma RP; Hammond PJ; Gomis R; Kerr D; Bruttomesso D; Bouter KP; Wiefels KJ; de la Calle H; Schweitzer DH; Pfohl M; Torlone E; Krinelke LG; Bolli GB;
    Diabet Med; 2006 Feb; 23(2):141-7. PubMed ID: 16433711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Continuous subcutaneous insulin infusion is sometimes a good choice in case of poorly regulated diabetes mellitus type I].
    Hoogma RP; de Vries JH; Michels RP; Hoekstra JB; Levi M
    Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2261-4. PubMed ID: 16240848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between continuous subcutaneous insulin infusion and multiple injections of insulin. A one-year prospective study.
    Schiffrin A; Belmonte MM
    Diabetes; 1982 Mar; 31(3):255-64. PubMed ID: 6759242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous subcutaneous insulin infusion in the treatment of juvenile-onset diabetes.
    Buysschaert M; Lejeune M; Lambert AE
    Diabete Metab; 1981 Sep; 7(3):189-93. PubMed ID: 7319116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a novel short-term continuous subcutaneous insulin infusion program evaluated by continuous glucose monitoring on young adult type 1 diabetic patients in Taiwan.
    Lin CH; Huang CH; Tsai JS; Hsieh SH; Sun JH; Huang BY; Huang MJ; Huang YY
    Endocr J; 2011; 58(10):835-40. PubMed ID: 21828934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes.
    Pickup J; Keen H
    Diabetes Care; 2002 Mar; 25(3):593-8. PubMed ID: 11874953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice.
    Evans M; Ceriello A; Danne T; De Block C; DeVries JH; Lind M; Mathieu C; Nørgaard K; Renard E; Wilmot EG
    Diabetes Obes Metab; 2019 Sep; 21(9):2039-2047. PubMed ID: 31144428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial.
    Aronson R; Li A; Brown RE; McGaugh S; Riddell MC
    Lancet Diabetes Endocrinol; 2020 Jun; 8(6):511-523. PubMed ID: 32445738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of use of specific features of subcutaneous insulin infusion systems and their relationship to metabolic control in patients with type 1 diabetes.
    Quirós C; Patrascioiu I; Giménez M; Vinagre I; Vidal M; Jansà M; Conget I
    Endocrinol Nutr; 2014; 61(6):318-22. PubMed ID: 24533929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.